Antimicrobial Resistance in Uropathogenic *Escherichia coli* Strains Isolated from Beasat Hospital in Sanandaj, West of Iran

Nasrin Bahmani[1*], Noshin Abdolmaleki[2] and Afshin Bahmani[3]

[1]*Zoonose Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran.*
[2]*Department of Medical Microbiology, Toohid Hospital, Kurdistan University of Medical Sciences, Sanandaj, Iran.*
[3]*Department of Public Health, Faculty of Health, Social Determinants of Health Research Center, Kurdistan University of Medical Sciences, Sanandaj, Iran.*

Original Research Article

ABSTRACT

Background and Objectives: Urinary tract infection (UTI) is one of the most frequent infectious diseases which is caused by Gram-negative bacteria especially *Escherichia coli.* Multiple resistance to antimicrobial agents are increasing quickly in *E. coli* isolates and may complicate therapeutic strategies for UTI. The propose of this study was to determine the antibiotic resistance patterns and the multidrug-resistance (MDR) phenotypes in uropathogenic *E. coli* (UPEC).
Materials and Methods: A total of 153 UPEC isolates were collected from both hospitalized patients (95 isolates) and outpatients (58 isolates) from March to October 2018. In order to determine the MDR among UPEC isolates, we have tested 15 antimicrobial agents on Muller Hinton agar by the disk diffusion method.
Results: The percentage of MDR isolates (resistant to at least three drug classes such as fluoroquinolones, penicillins and cephalosporins) was 55.5% in the hospitalized patients and the

Corresponding author: E-mail: na.bahmani@iran.ir;

outpatients. Antibiotic resistance to ampicillin, ceftazidime, nalidixic acid and trimethoprim/ sulfamethoxazole was higher than 60%. Meropenem, Imipenem and norfloxacin indicated markedly greater activity (93.3%, 80% and 85.6%, respectively) than other antimicrobial agents.

Conclusions: Urinary tract infection due to MDR *E. coli* may be difficult to treat empirically due to high resistance to commonly used antibiotics, so, empirical antibiotic treatment should be reviewed periodically at local studies.

1. INTRODUCTION

Urinary tract infections (UTIs), are the most common infections and are mainly caused by Gram-negative bacteria especially uropathogenic *Escherichia coli* [1].

E. coli is a kind of bacteria with diverse species that naturally found in the intestinal tract of all humans and many other animal species. A number of *E. coli* are a cause of enteric/diarrheal disease, and another subset causes extra-intestinal disease, including urinary tract infection (UTI) [2]. *E. coli* accounts for as many as 90% of all UTIs seen among ambulatory populations [3].

A UTI is defined as a significant number of pathogenic microorganisms in the urinary system. If there are symptoms such as frequent urination, painful or blood in the urine, only 100 uropathogenic bacteria per ml of urine may be significant [4]. According to studies, urinary tract infections (UTIs), including cystitis (when infection is limited to the bladder) and pyelonephritis (when the kidney is infected), are one of the most common infections in humans. Urinary tract infections often occur in patients with normal and functional urinary tracts [5]. The severity of the infection varies depending on the virulence of infecting bacteria and host susceptibility [6]. UPEC isolates which have virulence factors such as Fimbria or Pilli adhesions stimulate colonization of the bacteria and urinary tract infection; that mediate attachment to uroepithelial cells and initiate infections [7]. Clinical experiences have shown high levels of antibiotic resistance among the uropathogens. Overuse of antibiotics is the most important factor in increasing multidrug resistance (MDR) in UPEC isolates [8]. Antibiotic resistance is a serious problem in public health caused by UPEC and leading to increased morbidity and mortality. Due to the risk of kidney damage and complications, early diagnosis and treatment of the disease are important [9]. UTI cause several complex symptoms, physicians begin empirical antibiotic treatment before getting the culture results because urine culture and susceptibility agent results take about 4 days to

be prepared [10]. According to reports, the prevalence of MDR *E. coli* causing UTIs in the USA, Japan, China, India, Brazil, Saudi Arabia, and Nepal, is increasing [11,12]. Therefore the current study was proposed to determine the frequency of MDR *E. coli* among UTI isolates from a university medical center Besat Hospital, in Sanandaj west of Iran.

2. MATERIALS AND METHODS

2.1 Bacterial Isolates

In this study, a total 153 strains of bacteria causing UTIs collected from urine specimens in hospitalized patients or referred (outpatients) to Beast hospital from March to October 2018, in Sanandaj, west of Iran. The urine samples were collected by clean-catch midstream method and transported to the laboratory within one hour of collection. Diagnosis of *E. coli* isolates has been done according to standard microbiological methods [13]. The samples were cultured on MacConkey agar, Eosin-methylene blue agar and blood agar (Himedia Co, India). The plates were incubated at 35°C for 24 h. Bacteriological and biochemical tests were performed for confirmation of *E. coli* strains which included Gram-stain, oxidase, catalase, indole production, citrate utilization, methyl red, Voges Proskauer, lysine iron agar, triple sugar iron agar utilization, and urea test [11]. The positive control was tested by *E. coli* ATCC25922.

2.2 Antibiotic Susceptibility Test

Antibacterial susceptibility testing was performed using the Kirby–Bauer disk diffusion method on Muller Hinton agar medium. Isolates were declared as sensitive or resistant on the basis of the zone of inhibition according to the Clinical and Laboratory Standards Institute guidelines (CLSI) [14]. The antibiotic disks used in this study were ciprofloxacin (CIP) (5 μg), cefixime (CFM) (30 μg), norfloxacin (NOR)(10 μg),), nalidixic acid (NAL) (30 μg), gentamicin (GEN) (10 μg), amikacin(AMK) (30 μg), ampicillin (AMP) (10 μg), nitrofurantoin (NIT) (300 μg), trimethoprim/sulfamethoxazole (SXT) (1.75/23.75

µg), meropenem (MEM)(10 µg), Imipenem (IPM)(10 µg), cefepime (CPM) (30 µg), ceftazidime (CAZ) (30 µg), cefotaxime (CTX) (30 µg) and Cefuroxime (CFX) (30 µg). *E. coli* ATCC25922 was used as a positive control strain. Then the data analyzed by Whonet 5.6 (WHO, Geneva, Switzerland) Software. According to the results if on isolate was resistant to at least three of the antimicrobial classes, such as fluoroquinolones, amino-glycosides, cephalosporins, or carbapenems is considered as MDR isolate.

3. RESULTS

A total of 153 *E. coli* strains isolated from urine specimens with a count of more than 10^5 CFU/ML. The frequency of *E. coli* isolates in females (79%) was higher than males (21%). The age of patients ranged between 1 and 80 years. The number of *E. coli* strains were recovered from hospitalized patients and outpatients were 95(62%) and 58 (38%), respectively. Antibiotic resistance to AMP, NAL, CAZ and SXT was higher than 60%. The rates of resistance to AMP, SXT, CAZ, NAL, and CTX in hospitalized patients were higher than outpatients. The highest antibacterial agent's susceptibility has shown in meropenem, imipenem and norfloxacin (Fig. 1). Of the 153 *E. coli* isolates, 85 (55.5%) isolates were multidrug-resistant.

4. DISCUSSION

UTIs are serious health affecting problems worldwide. Urinary tract infections caused by uropathogenic *E. coli* are one of the most common infectious diseases that lead to renal failure [15]. The results of our study showed that

UTI in females (79%) was higher than males (21%) which were similar to the findings of Shah et al. [16]. Antibacterial agents are the most important products in twentieth-century used to kill or inhibit the growth of microorganisms. Antibiotic resistance in *E. coli* isolated from UTIs is increasing and it is a major public health problem. Therefore, it is very important to determine the antibiotic resistance patterns in *E. coli* isolates for accurate and proper prescriptions.

In the current study, most of *E. coli* isolates were resistant to ampicillin which indicating a cautious use of this antibiotic for the treatment of UTI. *E. coli* resistance to penicillin antibiotics have been increased in different parts of the world, but there are only a few reports which indicate 100% resistance to penicillins [17]. Resistance to other antibacterial agents such as ceftazidime (61%), cefepime (59.1%), cefotaxime (54.3%), and cefuroxime (48.4%), It was also very high, which was consistent with previous studies [18]. In the present study, the resistance of *E. coli* against meropenem (6.7%) and imipenem (20%) was lower than previous studies [19,20]. The results of our study showed that the meropenem and imipenem remain as effective antibacterial agents against *E. coli*.

The significant high resistance to SXT (64%) was found in the present study while many guidelines recommend this drug for UTIs [21]. In addition, variable resistance patterns were found for the aminoglycoside antibiotics. In our study, *E. coli* was highly resistant to gentamicin (45%), while a low level of resistance was observed for amikacin (21%). In a study by Ghazvini and et al. [22] *E. coli* resistance to gentamicin was 36.6%, which was lower compared to our study.


Fig. 1. Percentages of antibiotic resistance in *Escherichia coli* isolated from urine samples

Antibacterial agents including quinolones, especially ciprofloxacin have been used for *E. coli* infections in recent past years. In the present study, however, *E. coli* was resistant to ciprofloxacin (20%), which is not similar to the previous reports. Other fluoroquinolones such as norfloxacin (12.4% resistance) were found efficient for the *E. coli*. The studies from other parts of the world show that quinolones are still active against UTI infections [23].

Multiple drug resistance (MDR) in UPEC was also determined in this study. MDR is described as resistant to at least one member from three different antibiotic classes being used for the treatment of *E. coli*. Based on the results of the current study, there is a high resistance rate to the commonly used antibiotics in the *E. coli* isolates. From 153 *E. coli* isolates, 85 (55.5%) isolates were resistant to three or more antibiotics. The rates of antibiotic resistance in our study were different from some studies.

The high percentage multidrug- resistant of all *E. coli* isolates reported by Tabasi et al. in 2015 (79%) [24] and in another study by Castillo et al. in 2018, multidrug-resistant strains prevalence of *E. coli* was 63.3% [25].

Some behavioral factors and socioeconomic, such as misuse and use of irregular antimicrobial agents and easy access to antibiotics without a prescription can help to antibiotic resistance by hospital physicians or unskilled practitioners. In this study, a high percentage of isolates showed an MDR phenotype. These alert resistances to commonly used antibiotics can affect the therapeutic strategies.

The successful empirical initial treatment is based on the susceptibility and resistance patterns acquiring from local data. Since these susceptibility patterns are constantly variable and may change in different geographical regions and institutions, regular monitoring of antimicrobial agents resistance may be necessary to formulate standard treatment guidelines for empirical therapy.

5. CONCLUSION

In our study, there is significant antimicrobial resistance to *E. coli* isolates in UTI from community and hospital in Sanandaj, west of Iran. Thus, Continuous monitoring for antimicrobial resistance of UPEC in order to prevent treatment failure and to improve strategies for reducing antibiotic-resistant microorganisms and to ensure the best treatment to UTI patients is necessary.

CONSENT

It is not application.

ETHICAL APPROVAL

This study was approved by the ethical committee of the Kurdistan University of Medical Science, Kurdistan, Iran (IR.MUK.REC.1397/5033)

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

1. Dehbanipour R, Rastaghi S, Sedighi M, Maleki N, Faghri J. High prevalence of multidrug-resistance uropathogenic *Escherichia coli* strains, Isfahan, Iran. Journal of Natural Science, Biology and Medicine. 2016;7(1):22.

2. Niranjan V, Malini A. Antimicrobial resistance pattern in *Escherichia coli* causing urinary tract infection among inpatients. Indian J Med Res. 2014;139: 945-8.

3. Johnson JR, Stamm WE. Urinary tract infections in women: Diagnosis and treatment. Annals of Internal Medicine. 1989;111(11):906-17.

4. Stamm WE. Recent developments in the diagnosis and treatment of urinary tract infections. West J Med. 1982;137(3):213.

5. Jalali HR, Pourbakhsh A, Fallah F, Eslami G. Genotyping of virulence factors of uropathogenic *Escherichia coli* by PCR. Nov Biomed. 2015;3:177-181.

6. Wang MC, Tseng CC, Wu AB, Lin WH, Teng CH, Yan JJ, Wu JJ. Bacterial characteristics and glycemic control indiabetic patients with *Escherichia coli* urinary tract infection. J Microbiol Immunol Infect. 2013;46:24-29.

7. Bien J, Sokolova O, Bozko P. Role of uropathogenic *Escherichia coli* virulence factors in development of urinary tract infection and kidney damage. Int J Nephrol 2012;1-15.

8. Soltani R, Ehsanpoor M, Khorvash F, Shokri D. Antimicrobial susceptibility pattern of extended-spectrum β-lactamase-producing bacteria causing

nosocomial urinary tract infections in an Iranian Referral Teaching Hospital. J Res Pharm Pract. 2014;3:6-11.

9.   Subcommittee on Urinary Tract Infection, Steering Committee on Quality Improvement and Management, Roberts KB. Urinary tract infection: Clinical practice guideline for the diagnosis and management of the initial UTI in febrile infants and children 2 to 24 months. Pediatrics. 2011;128:595-610.

10. Hooton TM. Clinical practice uncomplicated urinary tract infection. N Engl J Med. 2012; 366:1028-37.

11. Ishikawa K, Hayakawa S, Miyakawa S, Kusaka M, Shiroki R, Hoshinaga K. Survey of the susceptibility of urinary isolates to antibacterial agents in 2003. J Infect Chemother. 2005;11:44-7.

12. Ho PL, Wong RC, Yip KS, Loke SL, Leung MS, Mak GC, et al. Antimicrobial resistance in *Escherichia coli* outpatient urinary isolates from women: Emerging multidrug resistance phenotypes. Diagn Microbiol Infect Dis. 2007;59:439-45.

13. Tille P. Bailey & Scott's. Diagnostic Microbiology. China: Elsevier Health Sciences; 2013.

14. Cockerill FR, Clinical, Institute LS. Performance Standards for Antimicrobial Disk Susceptibility Testing: Approved Standard. Wayne, USA: National Committee for Clinical Laboratory Standards; 2012.

15. Hagan EC, Mobley HL. Uropathogenic *Escherichia coli* outer membrane antigens expressed during urinary tract infection. Infect Immune. 2007;75:3941-3949.

16. Shah PS, Cannon JP, Sullivan CL, Nemchausky B, Pachucki CT. Controlling antimicrobial use and decreasing micro-biological laboratory tests for urinary tract infections in spinal-cord-injury patients with chronic indwelling catheters. Am J Health Syst Pharm. 2005;62(1):74–77.

17. Olowe OA, Eniola KIT, Olowe RA, Olayemi AB. Starch paper technique is easy to detect beta lactamase detection from cases of diarrheagenic *Escherichia coli* in Osogbo. Life Sci J. 2007;4:72-74.

18. Aziz Q, Ali Z, Izhar M, Shah VH. Antimicrobial resistance; comparison of *Escherichia coli* in different areas of Lahore. Prof Med J. 2012;3.

19. Mangaiarkkarasi A, Erli AI, Gopal R. Antimicrobial susceptibility patterns of clinical isolates of gram-negative pathogens from a Teaching Hospital, Pondicherry. Res J Pharmaceutical, Biol Chem Sci. 2013;4(2).

20. Sabir S, Ahmad Anjum A, Ijaz TAsad A. Isolation and antibiotic susceptibility of E. coli from urinary tract infections in a Tertiary Care Hospital. Pak J Med Sci. 2014;30(2):389–392.

21. Wuorela M, Kouri T, Laato M, Lipponen P, Sammalkorpi K, Uhari M, et al. Update on current care guidelines: Urinary tract infections. Duodecim. 2011;127:2334-5.

22. Ghazvini Hosseinali, Taheri Keyvan, Edalati Elahe. Virulence factors and anti-microbial resistance in uropathogenic *Escherichia coli* strains isolated from cystitis and pyelonephritis. Turk J Med Sci. 2019;49:1-7.

23. Mavroidi A, Miriagou V, Liakopoulos A, Tzelepi E, Stefos A, Dalekos GN, et al. Ciprofloxacin-resistant *Escherichia coli* in Central Greece: Mechanisms of resistance and molecular identification. BMC Infect Dis. 2012;12.

24. Tabasi M, Karam MRA, Habibi M, Yekaninejad MS, Bouzari S. Phenotypic assays to determine virulence factors of uropathogenic *Escherichia coli* (UPEC) isolates and their correlation with antibiotic resistance pattern. Osong Public Health Res Perspect. 2015;6:261-268.

25. Flor Y. Ramírez-Castillo, Adriana C. Moreno-Flores, Francisco J. Avelar-González, Francisco Márquez-Díaz, An evaluation of multidrug-resistant *Escherichia coli* isolates in urinary tract infections from Aguascalientes, Mexico: cross-sectional study. Ann Clin Microbiol Antimicrob. 2018;17(3):1-13.

Peer-review history:
The peer review history for this paper can be accessed here:
http://www.sdiarticle4.com/review-history/47830